Related Experiment Video
Updated: Nov 27, 2025
07:17
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
11.7K
Marked Decrease in CA 19-9 Level Belies Rapidly Progressive Lymphangitic Carcinomatosis in a Case of Metastatic
Daniel A King1, Gino Pineda1, Iny Jhun2
1Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA.
Journal of Pancreatic Cancer
|December 3, 2020
Summary
The CA 19-9 tumor marker can be unreliable for tracking pancreatic cancer treatment. A patient showed improved CA 19-9 levels but developed widespread cancer, emphasizing the need for comprehensive monitoring.
Area of Science:
- Oncology
- Medical Diagnostics
- Cancer Biomarkers
Background:
- The carbohydrate antigen 19-9 (CA 19-9) is a widely used tumor marker for monitoring treatment efficacy in pancreatic ductal adenocarcinoma.
- It is often employed in conjunction with imaging studies to assess chemotherapy response.
Observation:
- This report details an atypical clinical case involving metastatic pancreatic cancer.
- The patient experienced a significant reduction in CA 19-9 levels.
- Paradoxically, this coincided with the development of extensive pulmonary lymphangitic carcinomatosis.
Findings:
- The observed discrepancy between declining CA 19-9 levels and rapid clinical deterioration due to widespread metastasis.
- Pulmonary lymphangitic carcinomatosis presented as a terminal event despite favorable tumor marker trends.
Implications:
- This case underscores the critical limitations of relying solely on the CA 19-9 tumor marker for evaluating treatment response in pancreatic cancer.
- It highlights the necessity of integrating clinical assessment and advanced imaging for a holistic understanding of disease progression.
- Further research may be warranted to explore alternative or complementary biomarkers for pancreatic cancer management.
